SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Winblad Bengt) "

Sökning: WFRF:(Winblad Bengt)

Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
1.
  • Eyjolfsdottir, H., et al. (författare)
  • Targeted delivery of nerve growth factor to the cholinergic basal forebrain of Alzheimer's disease patients: application of a second-generation encapsulated cell biodelivery device
  • 2016
  • Ingår i: Alzheimers Research & Therapy. - 1758-9193. ; 8
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Targeted delivery of nerve growth factor (NGF) has emerged as a potential therapy for Alzheimer's disease (AD) due to its regenerative effects on basal forebrain cholinergic neurons. This hypothesis has been tested in patients with AD using encapsulated cell biodelivery of NGF (NGF-ECB) in a first-in-human study. We report our results from a third-dose cohort of patients receiving second-generation NGF-ECB implants with improved NGF secretion. Methods: Four patients with mild to moderate AD were recruited to participate in an open-label, phase Ib dose escalation study with a 6-month duration. Each patient underwent stereotactic implant surgery with four NGF-ECB implants targeted at the cholinergic basal forebrain. The NGF secretion of the second-generation implants was improved by using the Sleeping Beauty transposon gene expression technology and an improved three-dimensional internal scaffolding, resulting in production of about 10 ng NGF/device/day. Results: All patients underwent successful implant procedures without complications, and all patients completed the study, including implant removal after 6 months. Upon removal, 13 of 16 implants released NGF, 8 implants released NGF at the same rate or higher than before the implant procedure, and 3 implants failed to release detectable amounts of NGF. Of 16 adverse events, none was NGF-, or implant-related. Changes from baseline values of cholinergic markers in cerebrospinal fluid (CSF) correlated with cortical nicotinic receptor expression and Mini Mental State Examination score. Levels of neurofilament light chain (NFL) protein increased in CSF after NGF-ECB implant, while glial fibrillary acidic protein (GFAP) remained stable. Conclusions: The data derived from this patient cohort demonstrate the safety and tolerability of sustained NGF release by a second-generation NGF-ECB implant to the basal forebrain, with uneventful surgical implant and removal of NGF-ECB implants in a new dosing cohort of four patients with AD.
  •  
2.
  • Besga, A., et al. (författare)
  • Differences in brain cholesterol metabolism and insulin in two subgroups of patients with different CSF biomarkers but similar white matter lesions suggest different pathogenic mechanisms
  • 2012
  • Ingår i: Neuroscience Letters. - 0304-3940 .- 1872-7972. ; 510:2, s. 121-126
  • Tidskriftsartikel (refereegranskat)abstract
    • Investigate possible associations of white matter hyperintensities (WMHs) with the metabolism of cholesterol and insulin in two subgroups of patients with memory complaints and different CSF A beta 42 and CSF tau levels. 59 patients from the memory clinic at Karolinska Hospital were included. Degree of WMHs was rated using the ARWMC scale and the following biomarkers were measured in CSF and plasma: insulin, cholesterol, lanosterol, lathosterol, and oxidized cholesterol metabolites. The WMHs in CSF control-like group correlated with increased brain cholesterol synthesis and reduced efflux of oxysterols and insulin in CSF. In the CSF AD-like group, the WMHs correlated with increased peripheral cholesterol metabolism. Despite having similar appearance on FLAIR images, the pathogenic mechanisms of WMHS are likely to be different in the two groups investigated.
  •  
3.
  • Eriksdotter-Jönhagen, Maria, et al. (författare)
  • Encapsulated cell biodelivery of nerve growth factor to the Basal forebrain in patients with Alzheimer's disease.
  • 2012
  • Ingår i: Dementia and geriatric cognitive disorders. - 1421-9824 .- 1420-8008. ; 33:1, s. 18-28
  • Tidskriftsartikel (refereegranskat)abstract
    • Degeneration of cholinergic neurons in the basal forebrain correlates with cognitive decline in patients with Alzheimer's disease (AD). Targeted delivery of exogenous nerve growth factor (NGF) has emerged as a potential AD therapy due to its regenerative effects on the basal forebrain cholinergic neurons in AD animal models. Here we report the results of a first-in-man study of encapsulated cell (EC) biodelivery of NGF to the basal forebrain of AD patients with the primary objective to explore safety and tolerability.
  •  
4.
  • Frisoni, G. B., et al. (författare)
  • Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers
  • 2017
  • Ingår i: Lancet Neurology. - : Lancet Ltd. - 1474-4422 .- 1474-4465. ; 16:8, s. 661-676
  • Tidskriftsartikel (refereegranskat)abstract
    • The diagnosis of Alzheimer's disease can be improved by the use of biological measures. Biomarkers of functional impairment, neuronal loss, and protein deposition that can be assessed by neuroimaging (ie, MRI and PET) or CSF analysis are increasingly being used to diagnose Alzheimer's disease in research studies and specialist clinical settings. However, the validation of the clinical usefulness of these biomarkers is incomplete, and that is hampering reimbursement for these tests by health insurance providers, their widespread clinical implementation, and improvements in quality of health care. We have developed a strategic five-phase roadmap to foster the clinical validation of biomarkers in Alzheimer's disease, adapted from the approach for cancer biomarkers. Sufficient evidence of analytical validity (phase 1 of a structured framework adapted from oncology) is available for all biomarkers, but their clinical validity (phases 2 and 3) and clinical utility (phases 4 and 5) are incomplete. To complete these phases, research priorities include the standardisation of the readout of these assays and thresholds for normality, the evaluation of their performance in detecting early disease, the development of diagnostic algorithms comprising combinations of biomarkers, and the development of clinical guidelines for the use of biomarkers in qualified memory clinics.
  •  
5.
  • Iacono, D., et al. (författare)
  • Neuropathologic Assessment of Dementia Markers in Identical and Fraternal Twins
  • 2014
  • Ingår i: Brain Pathology. - 1015-6305 .- 1750-3639. ; 24:4, s. 317-333
  • Tidskriftsartikel (refereegranskat)abstract
    • Twin studies are an incomparable source of investigation to shed light on genetic and non-genetic components of neurodegenerative diseases, as Alzheimer's disease (AD). Detailed clinicopathologic correlations using twin longitudinal data and post-mortem examinations are mostly missing. We describe clinical and pathologic findings of seven monozygotic (MZ) and dizygotic (DZ) twin pairs. Our findings show good agreement between clinical and pathologic diagnoses in the majority of the twin pairs, with greater neuropathologic concordance in MZ than DZ twins. Greater neuropathologic concordance was found for -amyloid than tau pathology within the pairs. ApoE4 was associated with higher -amyloid and earlier dementia onset, and importantly, higher frequency of other co-occurring brain pathologies, regardless of the zygosity. Dementia onset, dementia duration, difference between twins in age at dementia onset and at death, did not correlate with AD pathology. These clinicopathologic correlations of older identical and fraternal twins support the relevance of genetic factors in AD, but not their sufficiency to determine the pathology, and consequently the disease, even in monozygotic twins. It is the interaction among genetic and non-genetic risks which plays a major role in influencing, or probably determining, the degeneration of those brain circuits associated with pathology and cognitive deficits in AD.
  •  
6.
  • Kadir, Ahmadul, et al. (författare)
  • Effect of phenserine treatment on brain functional activity and amyloid in Alzheimer's disease.
  • 2008
  • Ingår i: Annals of neurology. - 1531-8249 .- 0364-5134. ; 63:5, s. 621-31
  • Tidskriftsartikel (refereegranskat)abstract
    • OBJECTIVE: The effects of (-)-phenserine (phenserine) and placebo/donepezil treatment on regional cerebral metabolic rate for glucose (rCMRglc) and brain amyloid load were investigated by positron emission tomography in 20 patients with mild Alzheimer's disease in relation to cerebrospinal fluid (CSF) and plasma biomarkers, and cognitive function. METHODS: The first 3 months of the study was a randomized, double-blind, placebo-controlled phase, during which 10 patients received phenserine (30 mg/day) and 10 patients the placebo. Three to 6 months was an open-label extension phase, during which the placebo group received donepezil (5 mg/day) and the phenserine group remained on phenserine. After 6 months, all patients received phenserine treatment up to 12 months. The patients underwent positron emission tomography examinations to measure rCMRglc (8F-FDG) and amyloid load (11C-PIB) at baseline and after 3 and 6 months of the treatment. Neuropsychological and biomarker data were collected at the three times of positron emission tomography imaging. RESULTS: Statistically significant effects on a composite neuropsychological test score were observed in the phenserine-treated group compared with the placebo and donepezil group at 3 and 6 months, respectively. Values of rCMRglc were significantly increased in several cortical regions after 3 months of phenserine treatment, compared with baseline, and correlated positively with cognitive function and CSF beta-amyloid 40 (Abeta40). Cortical Pittsburgh Compound B retention correlated negatively with CSF Abeta40 levels and the ratio Abeta/beta-secretase-cleaved amyloid precursor protein. In CSF, Abeta40 correlated positively with the attention domain of cognition. INTERPRETATION: Phenserine treatment was associated with an improvement in cognition and an increase in rCMRglc.
  •  
7.
  •  
8.
  • Smailovic, U., et al. (författare)
  • Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer's Disease
  • 2021
  • Ingår i: Journal of Alzheimers Disease. - : IOS Press. - 1387-2877 .- 1875-8908. ; 83:1, s. 355-366
  • Tidskriftsartikel (refereegranskat)abstract
    • Background: Cerebrospinal fluid (CSF) neurogranin and quantitative electroencephalography (qEEG) are potential molecular and functional markers of synaptic pathology in Alzheimer's disease (AD). Synaptic markers have emerged as candidate prognostic indicators of AD since synaptic degeneration was shown to be an early event and the best correlate of cognitive deficits in patients along the disease continuum. Objective: The present study investigated the association between CSF neurogranin and qEEG measures as well as their potential to predict clinical deterioration in mild cognitive impairment (MCI) patients. Methods: Patients diagnosed with MCI (n = 99) underwent CSF conventional AD biomarkers and neurogranin analysis and resting-state EEG recordings. The study population was further stratified into stable (n = 41) and progressive MCI (n = 31), based on the progression to AD dementia during two years follow-up. qEEG analysis included computation of global field power and global field synchronization in four conventional frequency bands. Results: CSF neurogranin levels were associated with theta power and synchronization in the progressive MCI group. CSF neurogranin and qEEG measures were significant predictors of progression to AD dementia, independent of baseline amyloid status in MCI patients. A combination of CSF neurogranin with global EEG power in theta and global EEG synchronization in beta band exhibited the highest classification accuracy as compared to either of these markers alone. Conclusion: qEEG and CSF neurogranin are independent predictors of progression to AD dementia in MCI patients. Molecular and neurophysiological synaptic markers may have additive value in a multimodal diagnostic and prognostic approach to dementia.
  •  
9.
  •  
10.
  • Agüero-Torres, Hedda, et al. (författare)
  • Institutionalization in the elderly : The role of chronic diseases and dementia. Cross-sectional and longitudinal data from a population-based study
  • 2001
  • Ingår i: Journal of Clinical Epidemiology. - : Elsevier. - 0895-4356 .- 1878-5921. ; 54:8, s. 795-801
  • Tidskriftsartikel (refereegranskat)abstract
    • A population-based study of 1810 persons, aged 75+, was investigated to evaluate the role of dementia and other chronic diseases as determinants of institutionalization in the elderly. The study population was examined at baseline and after a 3-year interval. After adjustment for sociodemographic characteristics, functional dependence, dementia, cerebrovascular disease and hip fracture were associated with living in an institution at baseline. Additionally, functional dependence, hip fracture and dementia were also associated with moving to an institution during the 3-year follow-up. In a similar analysis, including only nondemented subjects, the Mini-Mental State Examination emerged as one of the strongest determinants. The population attributable risk percentage of institutionalization during the 3-year follow-up due to dementia was 61%. This study confirms that dementia and cognitive impairment are the main contributors to institutionalization in the elderly, independently of their sociodemographic status, social network, or functional status.
  •  
Skapa referenser, mejla, bekava och länka
Typ av publikation
tidskriftsartikel (200)
doktorsavhandling (7)
forskningsöversikt (6)
konferensbidrag (3)
bokkapitel (2)
rapport (1)
visa fler...
visa färre...
Typ av innehåll
refereegranskat (199)
övrigt vetenskapligt (20)
Författare/redaktör
Winblad, Bengt (203)
Winblad, B (148)
Blennow, K (29)
Fratiglioni, Laura (29)
Wimo, Anders (27)
Eriksdotter, Maria (27)
visa fler...
Fratiglioni, L (25)
Wimo, A (24)
Blennow, Kaj, 1958 (21)
Zetterberg, H. (20)
Kivipelto, Miia (20)
Religa, D (19)
Jelic, Vesna (19)
Kramberger, MG (17)
Andreasen, Niels (17)
Andreasen, N (16)
Kivipelto, M (15)
Zetterberg, Henrik, ... (14)
Kramberger, Milica G ... (14)
von Strauss, Eva (13)
Nordberg, Agneta (13)
Graff, Caroline (13)
Graff, C (13)
Jelic, V (13)
Kilander, Lena (13)
Fastbom, Johan (13)
Nordberg, A (12)
Scheltens, P (12)
Soininen, Hilkka (12)
Visser, PJ (12)
Visser, Pieter Jelle (12)
Aarsland, Dag (11)
Kareholt, I (11)
Hillerås, Pernilla (11)
von Strauss, E (11)
Kilander, L (11)
Fastbom, J (11)
Scheltens, Philip (10)
Blennow, Kaj (10)
Qiu, Chengxuan (10)
Johnell, Kristina (10)
Nägga, Katarina (10)
Almkvist, Ove (9)
Soininen, H (9)
Kåreholt, Ingemar (9)
Wahlund, Lars-Olof (9)
Molinuevo, JL (9)
Solomon, Alina (9)
Behbahani, Homira (9)
Mohammed, Abdul K. H ... (9)
visa färre...
Lärosäte
Karolinska Institutet (98)
Stockholms universitet (54)
Uppsala universitet (41)
Göteborgs universitet (36)
Röda Korsets Högskola (26)
Umeå universitet (19)
visa fler...
Lunds universitet (17)
Linköpings universitet (14)
Jönköping University (12)
Linnéuniversitetet (12)
Sophiahemmet Högskola (11)
Örebro universitet (9)
Luleå tekniska universitet (8)
Kungliga Tekniska Högskolan (6)
Karlstads universitet (2)
Mälardalens högskola (1)
Högskolan i Skövde (1)
Chalmers tekniska högskola (1)
Ersta Sköndal Bräcke högskola (1)
Sveriges Lantbruksuniversitet (1)
visa färre...
Språk
Engelska (209)
Svenska (9)
Italienska (1)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (148)
Samhällsvetenskap (14)
Naturvetenskap (8)
Teknik (2)

År

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy